Aldoxorubicin Bests Doxorubicin in Soft Tissue Sarcoma

Share this content:

the Cancer Therapy Advisor take:

The current standard of care for soft tissue sarcomas is doxorubicin, but results from a phase 2b study, which were presented at the 2014 ASCO Annual Meeting, indicate that aldoxorubicin may be a better first-line treatment option. Among patients randomly assigned treatment with aldoxorubicin, progression-free survival (PFS) was significantly improved by 79% to 104%. Overall response rate (ORR), which ranged from 21.7% to 23.8% in the aldoxorubicin group, was also considerably better than that observed in the doxorubicin group (0% to 5%). Further, the percentage of patients who experienced some tumor shrinkage was higher in the aldoxorubicin group (60.8% to 64.5%) versus the doxorubicin group (39.4% to 41.2%). In terms of safety, the researchers reported that toxicities of aldoxorubicin were consistent with those of doxorubicin. More patients receiving aldoxorubicin, however, experienced grade 3 and grade 4 treatment-related adverse events, including neutropenia, mucositis, and nausea or vomiting. None were treatment-limiting, according to the researchers, and cardiotoxicity was lower than in the doxorubicin group. Aldoxorubicin continues to be studied in a global phase 3 trial.

Colored scanning electron micrograph of sarcoma cells
Aldoxorubicin Bests Doxorubicin in Soft Tissue Sarcoma

(BUSINESS WIRE)-- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs